Albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Gustavo Bounous was a research medical doctor. He was born in Luserna, Italy on July 10, 1928. He was educated at the University of Turin and at the University of Genoa. Then, he worked as a research fellow in surgery at the Indiana Medical Center. In 1963 he moved to Canada. He became a professor of surgery, successively at the Université de Sherbrooke, 1973–1985, after that, at McGill University, 1985–1993. He died at the age of 83 on December 29, 2011.
==== Scalp hair loss ==== Prostaglandin D2 synthase (PTGDS) is an enzyme that produces PGD2. In men with androgenic alopecia, the enzyme PTGDS is elevated in the bald scalp tissue, as well as its product PGD2. PGD2 inhibits the growth of hair follicles through its activity on the DP2 receptor, but not the DP1 receptor. Theoretically, setipiprant's DP2 receptor antagonism may counteract the activity of PGD2 in hair follicles, thereby stimulating hair growth.
=== Mitral regurgitation === Surgery is recommended for chronic severe mitral regurgitation in symptomatic patients with left ventricular ejection fraction (LVEF) of greater than 30%, and asymptomatic patients with LVEF of 30-60% or left ventricular end diastolic volume (LVEDV) > 40%. Surgical repair of the leaflets is preferred to mitral valve replacement as long as the repair is feasible. Mitral regurgitation may be treated medically with vasodilators, diuretics, digoxin, antiarrhythmics, and chronic anticoagulation. Mild to moderate mitral regurgitation should be followed with echocardiography and cardiac stress test every 1–3 years. Severe mitral regurgitation should be followed with echocardiography every 3–6 months.
== See also == Protein serine/threonine phosphatase, enzyme for reverse process. Pseudokinase, a protein without enzyme activity (pseudoenzyme). It can be related to proteins of this class. ATM serine/threonine kinase, responsible for the disorder ataxia–telangiectasia.
Sources: en.wikipedia.org
=== Solvent process === The process involves transesterification of sucrose and triglycerides under a basic condition at 90 °C. DMF was used as a solvent at first, but was later substituted with dimethyl sulfoxide or DMSO, which is less hazardous and cheaper. This process produces a mixture of sucrose monoesters and more substituted esters at about a 5:1 ratio.
The first MP, installed at Yale in 1963, operated consistently at 10–11 megavolts; a later installation at Strasbourg reached 18. At these energies, electron stripping becomes highly efficient. A uranium ion passing through the terminal can lose more than 20 electrons, enabling heavy-ion fusion experiments impossible with earlier machines. Advances in gamma-ray spectroscopy combined with MP tandems enabled precision measurements of nuclear structure. HVEC manufactured 10 MP units between 1965 and 1973 for institutions including the University of Minnesota, Chalk River, and the Max Planck Institute in Heidelberg. The XTU ("Holy Roman Emperor") was designed for superheavy element synthesis. Theoretical models predicted an "island of stability" beyond element 110 where nuclei would resist rapid decay. The XTU's 20-megavolt rating would accelerate uranium ions to nearly one billion electron volts—enough to overcome Coulomb barriers in heavy-element fusion. Two prototypes operated solely on a test basis at Burlington before the project was cancelled. One later sold to Italy's national laboratory at Legnaro in 1979.
=== The Sean Duffy series === The Cold Cold Ground (Serpent's Tail) 2012 ISBN 978-1616147167 I Hear the Sirens in the Street (Serpent's Tail) 2013 ISBN 978-1616147877 In the Morning I'll Be Gone (Serpent's Tail) 2014 ISBN 978-1616148775 Gun Street Girl (Serpent's Tail) 2015 ISBN 978-1633880009 Rain Dogs (Serpent's Tail) 2016 ISBN 978-1633881303 Police at the Station and They Don't Look Friendly (Serpent's Tail) 2017 ISBN 1781256926 The Detective Up Late (Blackstone) 2023 Hang On St Christopher (Blackstone) 2025 The Ghosts Of Saturday Night TBD Two more Sean Duffy novels to be published by Blackstone Publishing On a blog post dated July 15, 2021, on his official site, McKinty explains that the 7th Sean Duffy novel (The Detective Up Late) may be out in late 2022. He states that The Detective Up Late is in fact finished and Book 8 (Hang On St Christopher) is pretty much done.
== Edwards Lecture Series == The Edwards Lecture Series is the longest-running lecture series at City, University of London, having reached its 44th edition in 2023. The lecture commemorates the work of physicist and Edwards Vacuum founder FD Edwards, a member of staff at City, University of London's predecessor institution, The Northampton Institute, and Past Master of the Worshipful Company of Scientific Instrument Makers. The lecture has a distinguished history and has been given by five Nobel Laureates over the years (Professor Denis Gabor, Professor Sir Harry Kroto, Professor Sir Peter Mansfield, Professor Sir Paul Nurse, and Professor Carlo Rubbia), as well as several Fellows of the Royal Society and Fellows of the Royal Academy of Engineering.
Collision avoidance system – a short range radar or LIDAR system on an automobile or vehicle that detects if the vehicle is about to collide with an object and applies the brakes to prevent the collision. Radar fuze – a detonator for an aerial bomb which uses a radar altimeter to measure the height of the bomb above the ground as it falls and detonates it at a certain altitude.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.